Parkinsons Disease Pipeline Insights
DelveInsight’s, “Parkinson’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Parkinson’s Disease Understanding
Parkinson’s Disease: Overview
Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson's develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Researchers have identified specific genetic mutations that can cause Parkinson's disease. But these are uncommon except in rare cases with many family members affected by Parkinson's disease. However, certain gene variations appear to increase the risk of Parkinson's disease but with a relatively small risk of Parkinson's disease for each of these genetic markers. Risk factors for Parkinson's disease include: Age- Young PDults rarely experience Parkinson's disease, Heredity - Having a close relative with Parkinson's disease increases the chances that you'll develop the disease, Sex - Men are more likely to develop Parkinson's disease than are women, Exposure to toxins - Ongoing exposure to herbicides and pesticides may slightly increase your risk of
"Parkinson’s Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s Disease pipeline landscape is provided which includes the disease overview and Parkinson’s Disease treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Parkinson’s Disease.
Parkinson’s Disease Emerging Drugs Chapters
This segment of the Parkinson’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Parkinson’s Disease Emerging Drugs
Tavapadon: Cerevel Therapeutics
Cerevel Therapeutics is developing Tavapadon for the treatment of both early- and late-stage Parkinson’s disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolerability profile.
P2B001, contains low doses of the dopamine agonists pramipexole, and the monoamine oxidase-B inhibitor rasagiline that have complementary mechanisms of action. Preclinical studies demonstrate that the combination provides synergistic effects, which are further enhanced if both agents are given in slow release. The synergy between the combination components implies that lower doses maybe used without compromising the therapeutic effect, while maintaining manageable safety profile, due to the decreased drug amounts. P2B001 is currently in phase III clinical study in the US, Canada and Europe.
Prasinezumab is a humanized monoclonal antibody that targets alpha-synuclein, a protein found in neurons that can aggregate and spread from cell to cell, resulting in the neuronal dysfunction and loss that causes Parkinson’s disease. Prasinezumab is designed to block the cell-to-cell transmission of the aggregated, pathogenic forms of alpha-synuclein in Parkinson's disease, thereby slowing clinical decline.
KDT-3594: Kissei Pharmaceutical
KDT-3594 is a novel orally administrable non-ergot dopamine agonist, which acts by stimulating dopamine receptors in the basal ganglia, thereby ameliorating the symptoms of Parkinson's Disease caused by insufficient action of dopamine. It is also confirmed as a new therapeutic agent for Parkinson's disease that KDT-3594 reduces the risk of the characteristic side effects of existing ergot and non-ergot dopamine agonists. KDT-3594 is currently under Phase 2 clinical trials in Japan.
MEDI1341 is an antibody that is differentiated by its high affinity, high selectivity and reduced effector function (lower interaction with the immune system), which has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies.
Further product details are provided in the report……..
Parkinson’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Parkinson’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Parkinson’s Disease
There are approx. 150+ key companies which are developing the therapies for Parkinson’s Disease. The companies which have their Parkinson’s Disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.
DelveInsight’s report covers around 150+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Parkinson’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Parkinson’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s Disease drugs.
Parkinson’s Disease Report Insights
- Parkinson’s Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Parkinson’s Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Parkinson’s Disease drugs?
- How many Parkinson’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Parkinson’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?